News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Eckert & Ziegler Enters Partnership with Molecular Partners to Support Development of Radio-DARPin Therapeutics
EQS-News: Eckert & Ziegler Enters Partnership with Molecular Partners to Support Development of Radio-DARPin Therapeutics
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
EQS-News: Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: BB Biotech AG publishes its 2025 annual report
EQS-Adhoc: BB Biotech AG publishes its 2025 annual report
EQS-News: Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization
EQS-News: Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
Today Bayer announced it has teamed up with former professional quarterback, Tony Romo, on ‘Highlights REAL,’ a campaign celebrating everyday moments. Tony is joined by his father Ramiro, who has
EQS-News: Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
EQS-News: Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
EQS-News: Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025
EQS-News: Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking